Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
29.14
-0.26 (-0.88%)
Nov 12, 2026, 4:00 PM EST - Market closed
Cogent Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 217.46 | 312.01 | 98.17 | 53.23 | 139.89 | 219.68 |
Short-Term Investments | 573.67 | 588.75 | 188.91 | 212.48 | 119.39 | - |
Cash & Short-Term Investments | 791.13 | 900.77 | 287.08 | 265.71 | 259.28 | 219.68 |
Cash Growth | 102.39% | 213.77% | 8.04% | 2.48% | 18.02% | -9.29% |
Prepaid Expenses | 12.45 | 9.59 | 9.4 | 5.06 | 4.44 | 2.95 |
Restricted Cash | - | - | - | - | 1.26 | - |
Total Current Assets | 803.58 | 910.36 | 296.47 | 270.77 | 264.97 | 222.63 |
Property, Plant & Equipment | 26.23 | 23.54 | 26.56 | 30.34 | 31.1 | 4.48 |
Long-Term Investments | - | - | - | 7.46 | - | - |
Other Long-Term Assets | 2.33 | 3.72 | 4.86 | 4.86 | 4.75 | 4.98 |
Total Assets | 832.14 | 937.61 | 327.9 | 313.44 | 300.81 | 232.09 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.94 | 9.5 | 12.01 | 10.66 | 5.84 | 3.48 |
Accrued Expenses | 63.26 | 46.16 | 41.76 | 25.69 | 17.48 | 7.98 |
Current Portion of Leases | 1.58 | 1.55 | 1.57 | 1.39 | 1.42 | 2.32 |
Other Current Liabilities | 2.34 | 6.75 | 0.37 | 0.44 | 2.1 | 3.3 |
Total Current Liabilities | 73.12 | 63.95 | 55.71 | 38.17 | 26.85 | 17.08 |
Long-Term Debt | 223.74 | 222.9 | - | - | - | - |
Long-Term Leases | 18.9 | 14.36 | 15.9 | 17.47 | 18.23 | 0.83 |
Other Long-Term Liabilities | 0.12 | 0.03 | - | - | - | - |
Total Liabilities | 315.88 | 301.24 | 71.61 | 55.64 | 45.08 | 17.91 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.17 | 0.16 | 0.11 | 0.09 | 0.07 | 0.04 |
Additional Paid-In Capital | 1,946 | 1,735 | 1,005 | 801.06 | 601.15 | 399.71 |
Retained Earnings | -1,494 | -1,188 | -859.48 | -603.62 | -411.21 | -270.97 |
Comprehensive Income & Other | -0.72 | 0.36 | 0.45 | 0.25 | -0.1 | - |
Total Common Equity | 451.51 | 546.98 | 145.69 | 197.77 | 189.91 | 128.78 |
Shareholders' Equity | 516.26 | 636.37 | 256.29 | 257.8 | 255.74 | 214.18 |
Total Liabilities & Equity | 832.14 | 937.61 | 327.9 | 313.44 | 300.81 | 232.09 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 244.22 | 238.8 | 17.47 | 18.85 | 19.65 | 3.16 |
Net Cash (Debt) | 546.91 | 661.97 | 269.61 | 254.32 | 239.63 | 216.53 |
Net Cash Growth | 65.56% | 145.53% | 6.01% | 6.13% | 10.67% | -8.63% |
Net Cash Per Share | 3.33 | 5.13 | 2.59 | 3.19 | 4.07 | 5.59 |
Filing Date Shares Outstanding | 174.04 | 161.05 | 110.54 | 103.91 | 69.95 | 45.81 |
Total Common Shares Outstanding | 174.03 | 161.05 | 110.54 | 86.12 | 69.89 | 43.81 |
Working Capital | 730.47 | 846.4 | 240.76 | 232.6 | 238.12 | 205.56 |
Book Value Per Share | 2.59 | 3.40 | 1.32 | 2.30 | 2.72 | 2.94 |
Tangible Book Value | 451.51 | 546.98 | 145.69 | 197.77 | 189.91 | 128.78 |
Tangible Book Value Per Share | 2.59 | 3.40 | 1.32 | 2.30 | 2.72 | 2.94 |
Machinery | - | 10.91 | 10.08 | 9.54 | 6.93 | 1.21 |
Construction In Progress | - | 0.76 | 0.04 | 0.03 | 0.48 | 0.65 |
Leasehold Improvements | - | 2.46 | 2.46 | 2.44 | 1.78 | 0.41 |